Cofrogliptin vs Evogliptin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline

Cofrogliptin

Marketed by Haisco Pharmaceutical Group

Phase 3 in Type 2 Diabetessmall molecule
Reliable signal

NCT04556851 · Phase 3 · completed

This randomized, double-blind, placebo-controlled trial enrolled 476 patients and measured change in HbA1c, a standard efficacy measure in diabetes, at 24 weeks. Both HSK7653 doses lowered HbA1c significantly more than placebo (p<0.0001), meeting the trial's primary goal.

Next expected readout: June 2027 · NCT07122102 (registry estimate)

Reported efficacy

HbA1c Change From Baseline at Week 24 (Baseline and week 24): HbA1c change from baseline to week 24 (LS mean, SE): cofrogliptin (HSK7653) 10 mg -0.96% (0.063), 25 mg -0.99% (0.064), linagliptin 5 mg -1.07% (0.065); non-inferiority margin of 0.4% met for both cofrogliptin doses vs linagliptin (met)

Result source: NCT04564872

Evogliptin · Suganon

Marketed by Dong-A ST and partners

Phase 3 in Type 2 Diabetessmall molecule
Reliable signal

NCT02949193 · Phase 3 · completed

This was a randomized, quadruple-blind, active-controlled trial (n=222) comparing evogliptin against sitagliptin, both added to metformin. The prespecified non-inferiority comparison for the primary endpoint, HbA1c change at 24 weeks, was met: the between-group difference and its confidence interval stayed within the non-inferiority range.

Reported efficacy

Change from baseline in HbA1c (%) After 24 weeks: Change in HbA1c from baseline: at week 24, LS mean difference evogliptin vs placebo -0.65% (95% CI -0.79 to -0.51, P<0.0001); at week 52, evogliptin -0.59% vs placebo -0.04% (LS mean difference -0.55%, 95% CI -0.71 to -0.39, P<0.0001) (met)

Result source: NCT04170998

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCofrogliptinEvogliptin
HbA1c, change-1.0% vs -1.1%avs linagliptin 5 mgcofrogliptin (HSK7653) 25 mg · wk 24NCT04564872
1 other result
  • -1.0% vs -1.1% cofrogliptin (HSK7653) 10 mg · wk 24 · Phase 3 · primary NCT04564872
-0.2% vs 0.1%a−0.3 vs placeboevogliptin 5mg · wk 24NCT02946541
2 other results
  • -0.6% vs -0.0% wk 52 · Phase 3 · primary NCT04170998
  • -0.6% vs -0.7% evogliptin 5mg · wk 24 · Phase 3 · primary NCT02949193
Body weight, change (kg)—Not posted · NCT04564872—Not posted · NCT02949193
HbA1c below 7%—Not posted · NCT04564872—Not posted · NCT02949193
Fasting plasma glucose, change—Not posted · NCT04564872—Not posted · NCT02949193
3-point MACE (% with event)—Not posted · NCT04564872—Not posted · NCT02949193

HbA1c, change

Cofrogliptin
-1.0% vs -1.1%avs linagliptin 5 mgcofrogliptin (HSK7653) 25 mg · wk 24NCT04564872
1 other result
  • -1.0% vs -1.1% cofrogliptin (HSK7653) 10 mg · wk 24 · Phase 3 · primary NCT04564872
Evogliptin
-0.2% vs 0.1%a−0.3 vs placeboevogliptin 5mg · wk 24NCT02946541
2 other results
  • -0.6% vs -0.0% wk 52 · Phase 3 · primary NCT04170998
  • -0.6% vs -0.7% evogliptin 5mg · wk 24 · Phase 3 · primary NCT02949193

Body weight, change (kg)

Cofrogliptin
—Not posted · NCT04564872
Evogliptin
—Not posted · NCT02949193

HbA1c below 7%

Cofrogliptin
—Not posted · NCT04564872
Evogliptin
—Not posted · NCT02949193

Fasting plasma glucose, change

Cofrogliptin
—Not posted · NCT04564872
Evogliptin
—Not posted · NCT02949193

3-point MACE (% with event)

Cofrogliptin
—Not posted · NCT04564872
Evogliptin
—Not posted · NCT02949193
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint

Coverage. Cofrogliptin: 1 of 1 rows · Evogliptin: 1 of 1 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCofrogliptin
Rows use multiple source trials
Evogliptin
Rows use multiple source trials
HbA1c
absolute change · percentage points
No placebo or comparator arm
-0.59% @ 24wk25 mga,b,c
NCT04556851 · Phase 3 · sponsor-reported, not registry data
show 1 more dose
-0.63% @ 24wkcofrogliptin (HSK7653) 10 mg
NCT04556851 · Phase 3 · sponsor-reported, not registry data
-0.65% @ 24wkb,c
NCT04170998 · Phase 3 · sponsor-reported, not registry data

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cofrogliptin's landscape · Evogliptin's landscape